CALLITAS HEALTH INC. Inactive Instrument
Callitas Health Inc. Share Price Canadian Securities Exchange
Equities
LILY
CA13125C1068
Biotechnology & Medical Research
| Sales 2018 | 0.75 1.03 60.05 | Sales 2019 | 0.71 0.97 56.77 | Capitalization | 3.53M 4.82M 282M |
|---|---|---|---|---|---|
| Net income 2018 | -5M -6.83M -400M | Net income 2019 | -1M -1.37M -80.05M | EV / Sales 2018 | 4,852,616 x |
| Net Debt 2018 | 319K 436K 25.54M | Net Debt 2019 | 848K 1.16M 67.86M | EV / Sales 2019 | 6,168,166 x |
| P/E ratio 2018 |
-0.6
x | P/E ratio 2019 |
-1.97
x | Employees | - |
| Yield 2018 * |
-
| Yield 2019 |
-
| Free-Float | 72.04% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 02/01/18 | |
Robert Payment
DFI | Director of Finance/CFO | 42 | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Skeith
BRD | Director/Board Member | 69 | 30/11/14 |
William Rodgers
BRD | Director/Board Member | - | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
Callitas Health Inc is a Canada-based company that is primarily engaged in integrated clinical-stage pharmaceutical development and over-the-counter (OTC) consumer goods marketing. The Company provides biomedical technologies and products. The Company offers drug treatments for obesity, infertility, intimacy issues, weight management, female sexual dysfunction solutions and women wellness.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
